Nanostructured lipid carriers for oral delivery of silymarin: Improving its absorption and in vivo efficacy in type 2 diabetes and metabolic syndrome model

被引:21
|
作者
Piazzini, Vieri [1 ]
Micheli, Laura [2 ]
Luceri, Cristina [2 ]
D'Ambrosio, Mario [2 ]
Cinci, Lorenzo [2 ]
Ghelardini, Carla [2 ]
Bilia, Anna Rita [2 ]
Mannelli, Lorenzo Di Cesare [2 ]
Bergonzi, Maria Camilla [1 ]
机构
[1] Univ Florence, Dept Chem, Via U Schiff 6, I-50019 Florence, Italy
[2] Univ Florence, Dept Neurosci Psychol Drug Res & Childrens Hlth, Sect Pharmacol & Toxicol, NEUROFARBA, Viale Pieraccini 6, I-50139 Florence, Italy
关键词
Silymarin; Nanostructured lipid carriers; PAMPA; Caco-2 cell line; Diabetes; Metabolic syndrome; MARIANUM L. GAERTN; HIGH-FAT DIET; OXIDATIVE STRESS; DRUG-DELIVERY; NANOPARTICLES; RAT; PERMEABILITY; VITRO; PERMEATION; PREDICTION;
D O I
10.1016/j.ijpharm.2019.118838
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Silymarin (SLM) is a mixture of flavonolignans extracted from the fruit of Silybum marianum L. Gaertn. which has been used for decades as a hepatoprotector. Silymarin has recently been proposed to be beneficial in type 2 diabetic patients. Constituents of SLM are poorly water-soluble and low permeable compounds, with consequently limited oral bioavailability. This study aimed to investigate the possibility of delivery of SLM via nanostructured lipid carriers (NLCs) to overcome these issues and for preparation of an oral dosage form. NLCs were prepared through an emulsion/evaporation/solidifying method. Cetyl palmitate:Lauroglycol 90 was selected as the lipid mixture and Brij S20 as surfactant. NLCs were chemically and physically characterized. Encapsulation efficiency was more than 92%. The storage stability of the NLC suspension was also investigated and the freeze-drying process was taken into consideration. After assessing the stability of the formulation in a simulated gastrointestinal environment, the release of SLM was monitored in different pH conditions. In vitro experiments with artificial membranes (PAMPA) and Caco-2 cells revealed that the NLCs enhanced the permeation of SLM. Active processes are involved in the internalization of NLCs, as evidenced by cellular uptake studies. After preliminary toxicological studies, the formulation was studied in vivo in a streptozotocin (STZ)-induced diabetic mouse model in the presence of metabolic syndrome. The formulation was also compared to an NLC containing stearic acid:Capryol 90, to evaluate the effect of the lipid matrix on the in vivo performance of nanocarriers. Finally, hepatic histopathological analyses were also conducted. Both SLM-loaded NLCs exhibited in vivo a significant down-regulation of blood glucose and triglyceride levels better than free SLM, with a liver-protective effect. Furthermore, both formulations showed a significant anti-hyperalgesic effect on STZ-induced neuropathy.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Nanostructured lipid carriers as oral delivery systems for improving oral bioavailability of nintedanib by promoting intestinal absorption
    Zhu, Yunjing
    Liang, Xue
    Lu, Cong
    Kong, Yihan
    Tang, Xing
    Zhang, Yu
    Yin, Tian
    Gou, Jingxin
    Wang, Yanjiao
    He, Haibing
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2020, 586
  • [2] Nanostructured lipid carriers for oral delivery of baicalin: In vitro and in vivo evaluation
    Luan, Jingjing
    Zheng, Fang
    Yang, Xiaoye
    Yu, Aihua
    Zhai, Guangxi
    [J]. COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS, 2015, 466 : 154 - 159
  • [3] Mucoadhesive nanostructured lipid carriers (NLCs) as potential carriers for improving oral delivery of curcumin
    Chanburee, Sanipon
    Tiyaboonchai, Waree
    [J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2017, 43 (03) : 432 - 440
  • [4] Nanostructured lipid carriers used for oral delivery of oridonin: An effect of ligand modification on absorption
    Zhou, Xiaotong
    Zhang, Xingwang
    Ye, Yanghuan
    Zhang, Tianpeng
    Wang, Huan
    Ma, Zhiguo
    Wu, Baojian
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2015, 479 (02) : 391 - 398
  • [5] Development of novel rosuvastatin nanostructured lipid carriers for oral delivery in an animal model
    Li, Jun
    Yang, Min
    Xu, Wenrong
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 2241 - 2248
  • [6] Nanostructured lipid carriers as novel ophthalmic delivery system for mangiferin: Improving in vivo ocular bioavailability
    Liu, Rui
    Liu, Zhidong
    Zhang, Chengui
    Zhang, Boli
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 101 (10) : 3833 - 3844
  • [7] Optimization of nanostructured lipid carriers of lamotrigine for brain delivery: in vitro characterization and in vivo efficacy in epilepsy
    Alam, Tausif
    Pandit, Jayamanti
    Vohora, Divya
    Aqil, Mohd
    Ali, Asgar
    Sultana, Yasmin
    [J]. EXPERT OPINION ON DRUG DELIVERY, 2015, 12 (02) : 181 - 194
  • [8] Formulation, optimization, and in-vivo evaluation of nanostructured lipid carriers loaded with Fexofenadine HCL for oral delivery
    Abdelhameed, Asmaa H.
    Abdelhafez, Wael A.
    Saleh, Kh, I
    Mohamed, Mohamed S.
    [J]. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2022, 74
  • [9] Oral Efficacy of a Diselenide Compound Loaded in Nanostructured Lipid Carriers in a Murine Model of Visceral Leishmaniasis
    Etxebeste-Mitxeltorena, Mikel
    Moreno, Esther
    Carvalheiro, Manuela
    Calvo, Alba
    Navarro-Blasco, Inigo
    Gonzalez-Penas, Elena
    Alvarez-Galindo, Jose, I
    Plano, Daniel
    Irache, Juan M.
    Almeida, Antonio J.
    Sanmartin, Carmen
    Espuelas, Socorro
    [J]. ACS INFECTIOUS DISEASES, 2021, 7 (12): : 3197 - 3209
  • [10] Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: Improving in vivo ocular distribution
    Shen, Jie
    Deng, Yanping
    Jin, Xuefeng
    Ping, Qineng
    Su, Zhigui
    Li, Lejun
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2010, 402 (1-2) : 248 - 253